Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Zepp Health Corporation Reports Third Quarter 2021 Unaudited Financial Results


      News provided by

      Zepp Health Corp.

      Nov 16, 2021, 05:30 ET

      Share this article

      Share this article


      BEIJING, Nov. 16, 2021 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today reported revenue of RMB1.6 billion (US$249.3 million); GAAP diluted net income per share of RMB0.19 (US$0.03); and GAAP diluted net income per ADS of RMB0.74 (US$0.11) for the third quarter ended September 30, 2021. Each ADS represents four (4) Class A ordinary shares.

      "Despite global supply chain and chip shortage challenges affecting many companies, we are pleased to meet our guidance range for the third quarter of 2021," said Wang Huang, Chairman and CEO of Zepp Health.  "Even without any new product launches, unit shipment volumes of Amazfit and Zepp branded products increased 89% year-over-year, demonstrating continuing global expansion of our brands. We began the fourth quarter with new technology and products, including our new OS for independent apps and the launch of the next generation 3 of our best-selling GT series watch line."

      "Today, our board approved a $20 million share repurchase program." Mr. Huang added, "The Share Repurchase Program is well aligned with our commitment to maximizing value for all of our stakeholders and reflects the Company's confidence in its sustainable growth and long-term strategy, supported by the strong balance sheet and cash position."

      Chief Financial Officer, Leon Deng, added "In addition to the strong growth of the Company's own branded products, third quarter topline performance reflected the different timing for the launch of Xiaomi's new Mi Band in the second quarter this year, as well as impacts of supply chain slowdowns and chip shortages. Despite these challenges, we successfully managed to continue our expense control, which reduced total operating expenses by 31.2%."

      Third Quarter 2021 Financial Summary










      For the Three Months Ended


      For the Nine Months Ended

      GAAP in millions, except for percentages
      and per share/ADS amounts


      Sept. 30,  

      2021

      Sept. 30,

      2020[1]


       Sept. 30,  

      2021

      Sept. 30,   

      2020[1]

      Revenue RMB


      1,606.1

      2,235.1


      4,588.5

      4,460.8

      Revenue US$


      249.3

      329.2


      712.1

      657.0

      Gross Margin


      20.2%

      20.6%


      21.5%

      21.5%

      Net income attributable to Zepp Health
      Corporation RMB


      49.3

      81.1


      101.5

      113.5

      Adjusted net income attributable to Zepp
      Health Corporation RMB[2]


      65.5

      120.8


      168.9

      165.5

      Diluted net income per share RMB


      0.19

      0.31


      0.38

      0.44

      Diluted net income per ADS US$


      0.11

      0.18


      0.24

      0.26

      Adjusted diluted net income per share RMB[3]


      0.25

      0.46


      0.64

      0.64

      Adjusted diluted net income per ADS US$


      0.15

      0.27


      0.40

      0.38

      Units Shipped


      9.9

      15.9


      27.8

      32.4

      [1] The US$ numbers in 2020 are referenced with the prior 6-K disclosures,which translations from RMB to US$ are made at a rate of RMB6.7896 to US$1.00, the effective noon buying rate for September 30, 2020 as set forth in the H.10 statistical release of the Federal Reserve Board.

      [2]Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

      [3] Adjusted diluted net income is the abbreviation of adjusted net income attributable to Zepp Health Corporation, which is a non-GAAP measure and excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted basic and diluted net income per ADS attributable to Zepp Health Corporation.

      Third Quarter 2021 Financial Results

      Revenue

      Total units shipped in the third quarter of 2021 decreased by 37.7% year-over-year to 9.9 million, compared with 15.9 million in the third quarter of 2020. This was driven by a 45.3% decrease in unit shipments of Xiaomi wearable products partially offset by a 88.9% increase in unit shippments of Amazfit and Zepp branded products.

      Revenues for the third quarter of 2021 reached RMB1.61 billion (US$249.3 million), a decrease of 28.1% from the third quarter of 2020, primarily as a result of decrease in sales of Xiaomi werable products as compared with the same period in 2020, which was due to the different launch time of Mi Band 5 and 6. Meanwhile, the revenue from our self-branded products increased, primarily driven by the sales of the Company's popular premium GT series, basic Bip and Pop models and rugged T-Rex.

      Both sequential and year-over-year quarterly revenue changes can be affected by fluctuations in seasonal purchase patterns as well as by the timing of new product introductions.

      Impact of COVID-19 on Our Business

      The global impact of the COVID-19 pandemic continued in the third quarter 2021, primarily manifesting as parts and supply chain challenges globally. The market is experiencing shortages of electronic components and chips for different industries, affecting the supply and production cycle for the Company, as well. Zepp Health had increased inventories of some parts, but supply chain delays of certain parts for a month affected production of finished goods. The Company cannot predict the potential, if any, future negative impact on market conditions or the Company's operations.

      Gross Margin

      Gross margin in the third quarter of 2021 was 20.2%, compared with 20.6% in the same period of 2020. Gross margin and gross profit are affected by product mix as different products have different margin contributions. These changes can also be influenced by the stage of the product in its lifecycle, product iterations and new product introductions.

      Research & Development

      Research and development expense in the third quarter of 2021 was RMB108.7 million, decreasing 37.1% year-over year, and comprising 6.8% of revenue, versus 7.7% in the same period last year. This reflects effective expense control in R&D activities and compensation from government subsidy. The company optimized its integrated product development process to effectively develop new smart devices and promoted its open platform ZEPP OS to welcome more outside developers to upload their apps and programs on the smart watches.

      Sales & Marketing

      Sales and Marketing expense in the third quarter of 2021 was RMB90.7 million, decreasing 21.5% year-over-year, and comprising 5.6% of revenue, compared with 5.2% of revenue in the same period in 2020. The decrease was due to effective expense control on marketing expenses while balancing investments to expand sales channels and markets around the world.

      General & Administrative

      General and Administrative expense was RMB61.9 million in the third quarter of 2021, decreasing 32.0% year-over-year, and comprising 3.9% of revenue, compared with 4.1% in the same period in 2020. The decrease was primarily due to the vesting of share-based compensation.

      Operating Expenses and Net Income

      Total operating expenses for the third quarter of 2021 were RMB261.3 million, a decrease of RMB118.2 million from the same period in 2020, comprising 16.3% of revenue, compared with 17.0% in the third quarter of 2020. 

      Operating income for the third quarter of 2021 was RMB62.5 million, a decrease of 22.5% from RMB80.6  million for the same period in 2020.

      Net income attributable to Zepp Health Corporation for the third quarter of 2021 was RMB49.3 million, compared with RMB81.1 million in the third quarter of 2020.

      Liquidity and Capital Resources

      As of September 30, 2021, the Company had cash and cash equivalents of RMB1,229.3 million (US$190.8 million), compared with RMB2,273.3 million as of December 31, 2020.

      Share Repurchase Program

      The Company's board of directors has approved a share repurchase program whereby the Company is authorized to repurchase up to US$20 million worth of its shares (including in the form of American depositary shares) over the next 12 months.

      The Company's proposed repurchases may be made from time to time in the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Company's board of directors will review the share repurchase program periodically, and may authorize adjustment of its terms and size. The Company expects to fund the repurchases out of its existing cash balance.‎

      Outlook

      For the fourth quarter of 2021, the management of the Company currently expects:

      -  Net revenues to be between RMB1.75 billion and RMB2.0 billion, compared with RMB1.97 billion in the fourth quarter of 2020. 

      This outlook reflects continuing uncertainty pertaining to the potential affects of the COVID-19 pandemic on sales and on electronic component delays, as well as expected sales seasonality of both self-branded and Xiaomi products. It is based on the current market conditions and reflects the Company management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.

      Conference Call

      The Company's management will hold a conference call at 7:30 a.m. Eastern Standard Time on Tuesday, November 16, 2021 (8:30 p.m. Beijing Time on November 16, 2021) to discuss financial results and answer questions from investors and analysts. Listeners may access the call by dialing:

      US (Toll Free):

      +1-888-346-8982

      International:

      +1-412-902-4272

      Mainland China (Toll Free):

      400-120-1203

      Hong Kong (Toll Free):

      800-905-945

      Hong Kong:

      +852-3018-4992

      Participants should dial-in at least 10 minutes before the scheduled start time and ask to be connected to the call for "Zepp Health Corporation."

      Additionally, a live and archived webcast of the conference call will be available at https://ir.zepp.com/investor.

      A telephone replay will be available one hour after the call until November 23, 2021 by dialing:

      US Toll Free:


      +1-877-344-7529

      International:


      +1-412-317-0088

      Replay Passcode:


      10161759

      About Zepp Health Corporation (NYSE: ZEPP)

      Zepp Health changed its name from Huami Corp. (HMI) on February 25, 2021 to emphasize its health focus with a name that resonates across languages and cultures globally. The company's mission continues to be connecting health with technology. Since its inception in 2013, Zepp Health has developed a platform of proprietary technology including AI chips, biometric sensors, and data algorithms, which drive a broadening line of smart health devices for consumers, and data analytics services for population health.  Zepp Health is one of the largest global developers of smart wearable health and consumer fitness devices, shipping 46 million units in 2020. Zepp Health Corp. is based in Hefei, China, with U.S. operations, Zepp Health USA, based in Cupertino, California. 

      Use of Non-GAAP Measures

      We use adjusted net income, a non-GAAP financial measure, in evaluating our operating results and for financial and operational decision-making purposes. Adjusted net income represents net income excluding share-based compensation expenses, and such adjustment has no impact on income tax. Adjusted net income attributable to Zepp Health Corporation is a non-GAAP measure, which excludes share-based compensation expenses attributable to Zepp Health Corporation, and is used as the numerator in computation of adjusted net income per share and per ADS attributable to Zepp Health Corporation.

      We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in net income and net income attributable to Zepp Health Corporation. We believe that adjusted net income and adjusted net income attributable to Zepp Health Corporation provides useful information about our operating results, enhances the overall understanding of our past performance and future prospects and allows for greater visibility with respect to key metrics used by our management in its financial and operational decision-making.

      Adjusted net income and adjusted net income attributable to Zepp Health Corporation, should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per share and per ADS attributable to Zepp Health Corporation. or any other measure of performance or as an indicator of our operating performance. Investors are encouraged to review the historical non-GAAP financial measures to the most directly comparable GAAP measures. Adjusted net income and adjusted net income attributable to ordinary shareholders, presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

      Exchange Rate

      The Company's business is primarily conducted in China and the significant majority of revenues generated are denominated in RMB. This announcement contains currency conversions of RMB amounts into US$ solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ are made at a rate of RMB6.4434 to US$1.00, the effective noon buying rate for September 30, 2021 as set forth in the H.10 statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on September 30, 2021, or at any other rate.

      Safe Harbor Statement

      This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the cooperation with Xiaomi, the recognition of the Company's self-branded products; the Company's growth strategies; trends and competition in global wearable technology market; changes in the Company's revenues and certain cost or expense accounting policies; governmental policies relating to the Company's industry and general economic conditions in China and the global. Further information regarding these and other risks is included in the Company's filings with the United States Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

      For investor and media inquiries, please contact:

      In China:
      Zepp Health Corporation
      Grace Yujia Zhang
      Email: [email protected]

      The Piacente Group, Inc.
      Yang Song
      Tel: +86-10-6508-0677
      Email: [email protected]

      In the United States:
      Zepp Health Corporation
      Brad Samson
      Tel: 1+714-955-3951
      Email: [email protected]  

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      As of December 31,


      As of September 30,



      2020


      2021



      RMB


      RMB


      US$








      Assets







      Current assets:







      Cash and cash equivalents


      2,273,349


      1,229,273


      190,780

      Restricted cash


      2,401


      298


      46

      Term deposit


      5,000


      5,000


      776

      Accounts receivable


      298,038


      415,626


      64,504

      Amounts due from related parties, current


      860,213


      761,725


      118,218

      Inventories, net


      1,217,537


      1,271,432


      197,323

      Short-term investments


      18,430


      19,358


      3,004

      Prepaid expenses and other current assets


      152,898


      204,425


      31,726

      Total current assets


      4,827,866


      3,907,137


      606,377








      Property, plant and equipment, net


      124,619


      142,810


      22,164

      Intangible asset, net


      145,213


      138,570


      21,506

      Goodwill


      62,515


      61,733


      9,581

      Long-term investments


      443,986


      1,536,659


      238,486

      Deferred tax assets


      120,190


      170,650


      26,484

      Other non-current assets


      28,165


      20,101


      3,120

      Non-current operating lease right-of-use assets


      151,165


      118,479


      18,388

      Total assets


      5,903,719


      6,096,139


      946,106

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      As of December 31, 


      As of September 30,



      2020


      2021



      RMB


      RMB


      US$








      Liabilities







      Current liabilities:







      Accounts payable


      1,951,335


      1,330,946


      206,560

      Advance from customers


      42,502


      45,039


      6,990

      Amount due to related parties, current


      11,185


      62,481


      9,697

      Accrued expenses and other current liabilities


      252,275


      189,993


      29,486

      Income tax payables


      27,706


      38,703


      6,007

      Short-term bank borrowings


      504,671


      458,000


      71,080

      Total current liabilities


      2,789,674


      2,125,162


      329,820

      Deferred tax liabilities


      22,374


      25,568


      3,968

      Long-term borrowing


      60,000


      726,865


      112,808

      Other non-current liabilities


      185,168


      229,670


      35,644

      Non-current operating lease liabilities


      116,245


      82,699


      12,835

      Total liabilities


      3,173,461


      3,189,964


      495,075

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)









      As of December 31,


      As of September 30,



      2020


      2021



      RMB


      RMB


      US$








      Equity







      Ordinary shares


      157


      159


      25

      Additional paid-in capital


      1,552,109


      1,629,644


      252,917

      Accumulated retained earnings


      1,133,368


      1,234,855


      191,646

      Accumulated other comprehensive income


      44,624


      37,768


      5,861

      Total Zepp Health Corporation shareholders' equity


      2,730,258


      2,902,426


      450,449

      Noncontrolling interests


      -


      3,749


      582

      Total equity


      2,730,258


      2,906,175


      451,031

      Total liabilities and equity


      5,903,719


      6,096,139


      946,106









      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      For the Three Months Ended September 30,




      2020


      2021




      RMB


      RMB


      US$










      Revenues


      2,235,093


      1,606,057


      249,256


      Cost of revenues


      (1,775,017)


      (1,282,308)


      (199,011)


      Gross profit


      460,076


      323,749


      50,245


      Operating expenses:








      Selling and marketing


      (115,617)


      (90,703)


      (14,077)


      General and administrative


      (90,987)


      (61,908)


      (9,608)


      Research and development


      (172,891)


      (108,663)


      (16,864)


      Total operating expenses


      379,495


      261,274


      40,549


      Operating income


      80,581


      62,475


      9,696


      Other income and expenses:








      Interest income


      10,330


      3,573


      555


      Interest expense


      (7,539)


      (13,490)


      (2,094)


      Other income, net


      1,785


      1,742


      270


      Gain from fair value change of long-term investment


      3,304


      -


      -


      Income before income tax and income from equity method
      investment


      88,461


      54,300


      8,427


      Income tax expenses


      (8,437)


      (6,229)


      (967)


      Income before loss from equity method investments


      80,024


      48,071


      7,460


      Net income from equity method investments


      2,472


      996


      155


      Net income


      82,496


      49,067


      7,615


      Less: Net income/(loss) attributable to noncontrolling interest


      1,422


      (278)


      (43)


      Net income attributable to Zepp Health Corporation


      81,074


      49,345


      7,658


      Net income per share attributable to Zepp Health Corporation








      Basic income per ordinary share


      0.33


      0.20


      0.03


      Diluted income per ordinary share


      0.31


      0.19


      0.03










      Net income per ADS (4 ordinary shares equal to 1 ADS)








      ADS – basic


      1.30


      0.78


      0.12


      ADS – diluted


      1.24


      0.74


      0.11










      Weighted average number of shares used in computing net income 
      per share

      Ordinary share – basic


      248,748,630


      252,495,778


      252,495,778


      Ordinary share – diluted


      260,829,357


      266,301,240


      266,301,240















      Zepp Health Corporation

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)










      For the Three Months Ended September 30, 2021



      2020


      2021



      RMB


      RMB


      US$








      Net income attributable to Zepp Health Corporation


      81,074


      49,345


      7,658

      Share-based compensation expenses


      39,723


      16,131


      2,503

      Adjusted net income attributable to Zepp Health
      Corporation [2]


       

      120,797


       

      65,476


       

      10,161








      Adjusted net income per share attributable to 
      Zepp Health Corporation







      Adjusted basic income per ordinary share


      0.49


      0.26


      0.04

      Adjusted diluted income per ordinary share


      0.46


      0.25


      0.04








      Adjusted net income per ADS (4 ordinary shares equal
      to 1 ADS)







      ADS – basic


      1.94


      1.04


      0.16

      ADS – diluted


      1.85


      0.98


      0.15








      Weighted average number of shares used in 
      computing adjusted net income per share







      Ordinary share – basic


      248,748,630


      252,495,778


      252,495,778

      Ordinary share – diluted


      260,829,357


      266,301,240


      266,301,240








      Share-based compensation expenses included 
      are follows:







      Selling and marketing


      556


      291


      45

      General and administrative


      21,033


      9,036


      1,402

      Research and development


      18,134


      6,804


      1,056

      Total


      39,723


      16,131


      2,503

      Zepp Health Corporation

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)




      For the Nine Months Ended September 30,



      2020


      2021



      RMB


      RMB


      US$








      Revenues


      4,460,828


      4,588,461


      712,118

      Cost of revenues


      (3,502,809)


      (3,603,471)


      (559,250)

      Gross profit


      958,019


      984,990


      152,868

      Operating expenses:







      Selling and marketing


      (241,802)


      (286,176)


      (44,414)

      General and administrative


      (197,293)


      (193,641)


      (30,053)

      Research and development


      (408,434)


      (421,297)


      (65,384)

      Total operating expenses


      847,529


      901,114


      139,851

      Operating income


      110,490


      83,876


      13,017

      Other income and expenses:







      Investment income


      -


      13,507


      2,096

      Interest income


      31,668


      13,826


      2,146

      Interest expense


      (16,312)


      (30,480)


      (4,730)

      Other income, net


      2,540


      4,027


      625

      Gain from fair value change of long-term investment


      4,597


      -


      -

      Income before income tax and income from equity method
      investment


      132,983


      84,756


      13,154

      Income tax expenses


      (12,956)


      (10,238)


      (1,589)

      Income before loss from equity method investments


      120,027


      74,518


      11,565

      Net income/(loss) from equity method investments


      (5,471)


      26,289


      4,080

      Net income


      114,556


      100,807


      15,645

      Less: Net income/(loss) attributable to noncontrolling interest


      1,007


      (681)


      (106)

      Net income attributable to Zepp Health Corporation


      113,549


      101,488


      15,751

      Net income per share attributable to Zepp Health Corporation







      Basic income per ordinary share


      0.46


      0.40


      0.06

      Diluted income per ordinary share


      0.44


      0.38


      0.06








      Net income per ADS (4 ordinary shares equal to 1 ADS)







      ADS – basic


      1.83


      1.61


      0.25

      ADS – diluted


      1.75


      1.54


      0.24








      Weighted average number of shares used in computing net
      income
       per share

      Ordinary share – basic


      248,080,549


      251,707,456


      251,707,456

      Ordinary share – diluted


      259,723,569


      264,369,709


      264,369,709













      Zepp Health Corporation

      Reconciliation of GAAP and Non-GAAP Results

      (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$")

      except for number of shares and per share data, or otherwise noted)










      For the Nine Months Ended September 30,



      2020


      2021



      RMB


      RMB


      US$








      Net income attributable to Zepp Health Corporation


      113,549


      101,488


      15,751

      Share-based compensation expenses


      51,936


      67,431


      10,465

      Adjusted net income attributable to Zepp Health Corporation [2]


      165,485


      168,919


      26,216








      Adjusted net income per share attributable to 
      Zepp Health Corporation







      Adjusted basic income per ordinary share


      0.67


      0.67


      0.10

      Adjusted diluted income per ordinary share


      0.64


      0.64


      0.10








      Adjusted net income per ADS (4 ordinary shares equal
      to 1 ADS)







      ADS – basic


      2.67


      2.68


      0.42

      ADS – diluted


      2.55


      2.56


      0.40








      Weighted average number of shares used in 
      computing adjusted net income per share







      Ordinary share – basic


      248,080,549


      251,707,456


      251,707,456

      Ordinary share – diluted


      259,723,569


      264,369,709


      264,369,709








      Share-based compensation expenses included 
      are follows:







      Cost of revenues


      (54)


      -


      -

      Selling and marketing


      1,820


      7,311


      1,135

      General and administrative


      28,963


      23,257


      3,609

      Research and development


      21,207


      36,863


      5,721

      Total


      51,936


      67,431


      10,465

      SOURCE Zepp Health Corp.

      Modal title

      Also from this source

      Zepp Health Corporation to Report Third Quarter 2026 Financial Results on November 22, 2026

      Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that ...

      Zepp Health Corporation Reports Second Quarter of 2026 Unaudited Financial Results

      Zepp Health Corporation (NYSE: ZEPP) ("Zepp", the "Company" or "we") today announced its unaudited financial results for the second quarter of 2026....

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Health Care & Hospitals

      Health Care & Hospitals

      Consumer Electronics

      Consumer Electronics

      Computer & Electronics

      Computer & Electronics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.